About Advanced Accelerator Applications
Advanced Accelerator Applications is a company based in Saint-genis-pouilly (France) founded in 2002 was acquired by Novartis in October 2017. Advanced Accelerator Applications has raised $56.13 million across 2 funding rounds from investors including Novartis and HBM Partners. Advanced Accelerator Applications has completed 3 acquisitions, including Atreus Pharmaceuticals, IDB Holland and PET Net. Advanced Accelerator Applications offers products and services including Radioligand Therapies and Radionuclide Molecular Imaging. Advanced Accelerator Applications operates in a competitive market with competitors including SOFIE, Mariana Oncology, AdvanCell, Ariceum Therapeutics and Lantheus, among others.
- Headquarter Saint-genis-pouilly, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Advanced Accelerator Applications
-
Annual Revenue
$235.08 M (USD)48as on Dec 31, 2023
-
Net Profit
$43.24 M (USD)21as on Dec 31, 2023
-
EBITDA
$43.24 M (USD)21as on Dec 31, 2023
-
Total Equity Funding
$56.13 M (USD)
in 2 rounds
-
Latest Funding Round
$283.07 K (USD), Grant
Apr 01, 2015
-
Investors
Novartis
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Atreus Pharmaceuticals
& 2 more
-
Acquired by
Novartis
(Oct 30, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Advanced Accelerator Applications
Advanced Accelerator Applications offers a comprehensive portfolio of products and services, including Radioligand Therapies and Radionuclide Molecular Imaging.
Targeted therapies using radioactive ligands to treat tumors effectively.
Imaging solutions for detecting and monitoring cancer progression.
Funding Insights of Advanced Accelerator Applications
Advanced Accelerator Applications has successfully raised a total of $56.13M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $283.07 thousand completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Advanced Accelerator Applications
Advanced Accelerator Applications has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis and HBM Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage life sciences investments are managed via VC and PE.
|
Locked | Locked | Locked | |
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for Advanced Accelerator Applications
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Advanced Accelerator Applications
Advanced Accelerator Applications has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Atreus Pharmaceuticals, IDB Holland and PET Net.
Investment portfolio details for Advanced Accelerator Applications
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Radiopharmaceutical devices are manufactured in the Netherlands.
|
Locked | Locked | 2016 | Locked | |
|
In vivo imaging diagnostics for autoimmune diseases are developed.
|
Locked | Locked | 2007 | Locked | |
|
Radiopharmaceuticals are manufactured by PET Net in Germany.
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for Advanced Accelerator Applications
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Advanced Accelerator Applications
Detailed financials for Advanced Accelerator Applications
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Advanced Accelerator Applications Comparisons
Peer comparison for Advanced Accelerator Applications
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Advanced Accelerator Applications
Advanced Accelerator Applications operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SOFIE, Mariana Oncology, AdvanCell, Ariceum Therapeutics and Lantheus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
|
| Locked | Locked | Locked |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| Locked | Locked | Locked |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| Locked | Locked | Locked |
Developer of diagnostic imaging agents and targeted therapeutics
|
Detailed competitors of Advanced Accelerator Applications
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Advanced Accelerator Applications
Complete news archive for Advanced Accelerator Applications
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Advanced Accelerator Applications
Advanced Accelerator Applications was founded in 2002 and raised its 1st funding round 12 years after it was founded.
Advanced Accelerator Applications is headquartered in Saint-genis-pouilly, France. It is registered at Saint-genis-pouilly, Ain, France.
Advanced Accelerator Applications is a funded company, having raised a total of $56.13M across 2 funding rounds to date.
Annual revenue of Advanced Accelerator Applications is $235.08M as on Dec 31, 2023.
Founded in 2002 as a spin-off from CERN in Geneva, Switzerland, Advanced Accelerator Applications operates in the nuclear medicine sector. Radiopharmaceuticals for PET and SPECT imaging in oncology, neurology, cardiology, and infectious diseases are developed, manufactured, and commercialized. The company, acquired by Novartis in 2017, is headquartered in Saint-Genis-Pouilly, France, with Lutathera approved by the FDA for treating certain neuroendocrine tumors.
Advanced Accelerator Applications's top competitors include SOFIE, AdvanCell and Mariana Oncology.
Advanced Accelerator Applications offers Radioligand Therapies and Radionuclide Molecular Imaging.
Advanced Accelerator Applications has made 3 acquisitions, including Atreus Pharmaceuticals, IDB Holland, and PET Net.
Advanced Accelerator Applications has 2 investors. Key investors include Novartis, and HBM Partners.